Rivaroxaban versus warfarin: differential effects on oxidative stress and fibrinolytic markers in atrial fibrillation
These results suggest that in patients with AF, rivaroxaban may provide pleiotropic benefits beyond anticoagulation, potentially by augmenting cellular antioxidant mechanisms and suppressing antifibrinolytic activity.
Authors
- Cláudia Natália Ferreira (ORCID: https://orcid.org/0000-0003-4545-6821)
- Gabriela Lopes Martins (ORCID: https://orcid.org/0000-0002-5152-8038)
- Rita Carolina Figueiredo Duarte (ORCID: https://orcid.org/0000-0002-4483-6489)
- Luana Bernardes Xavier Costa
- Edna Afonso Reis (ORCID: https://orcid.org/0000-0003-1465-9167)
- Carvalho Maria das Graças
- Francisco Rezende Silveira (ORCID: https://orcid.org/0000-0003-4135-6161)
- Luciene Bruno Vieira
- Karina Braga Gomes
- Helton Jose Reis
- Estêvão Lanna Figueiredo
- Nathália Greco Coelho
- Luma Clara Martins Costa
Institutions
- Universidade Federal de Minas Gerais (BR)
- Lifecenter Hospital (BR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-19
- DOI
- https://doi.org/10.3389/fphar.2026.1685101
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais